Mithra Pharmaceuticals S.A. Logo

Mithra Pharmaceuticals S.A.

Biotech firm developing pharma for women's health: contraception, fertility, and menopause.

MITRA | BR

Overview

Corporate Details

ISIN(s):
BE0974283153 (+1 more)
LEI:
5493002FDD273HTEKK14
Country:
Belgium
Address:
Rue Saint-Georges 5, 4000 Liège
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mithra Pharmaceuticals S.A. is a biotechnology company dedicated to women's health. The company specializes in the development, manufacturing, and commercialization of proprietary and over-the-counter pharmaceutical products. Its core focus areas include contraception, fertility, and menopause. Mithra's mission is to transform the women's health sector by providing innovative new choices that aim to improve the overall quality of life for women.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-06-11 10:00
M&A Activity
2024-06-11_Mithra_Press-Release_Mithra sells to GR_EN-FS (003) (002)-PDF.pdf
English 179.8 KB
2024-06-11 10:00
M&A Activity
2024-06-11_Mithra_Press-Release_Mithra sells to GR_FR-FS-PDF.pdf
French 126.7 KB
2024-06-10 19:15
Legal Proceedings Report
2024-06-10_Mithra_Press-Release_Mithra files for bankruptcy AND sells to GR_EN.…
English 181.9 KB
2024-06-10 19:15
Legal Proceedings Report
2024-06-10_Mithra_Press-Release_Mithra files for bankruptcy AND sells to GR_FR.…
French 128.7 KB
2024-06-04 08:00
Legal Proceedings Report
2024-0~1.PDF
English 153.0 KB
2024-06-04 08:00
Legal Proceedings Report
2024-0~2.PDF
French 158.7 KB
2024-05-28 15:00
Pre-Annual General Meeting Information
2024-05-28_Mithra_Press-release_Mithra postpones its annual general meeting_EN.…
English 139.6 KB
2024-05-28 15:00
Pre-Annual General Meeting Information
2024-05-28_Mithra_Press-release_Mithra postpones its annual general meeting_FR.…
French 143.3 KB
2024-05-10 16:30
Regulatory Filings
2024-05-10_Mithra_Press-release_Additional patent protection NEXSTELLIS_EN.pdf
English 124.3 KB
2024-05-10 16:30
Regulatory Filings
2024-05-10_Mithra_Press-release_Additional patent protection NEXSTELLIS_FR.pdf
French 126.5 KB
2024-05-03 17:30
M&A Activity
2024-05-03_Mithra_Press-release_Mithra Announces Exclusive Negotiations and Fun…
English 142.7 KB
2024-05-03 17:30
Capital/Financing Update
2024-05-03_Mithra_Press-release_Mithra Announces Exclusive Negotiations and Fun…
French 145.9 KB
2024-04-30 10:30
Proxy Solicitation & Information Statement
2024-04-30_MITHRA_VOTING-BY-MAIL-FORM_AGO-MAY-2024_EN.pdf
English 141.0 KB
2024-04-30 10:30
Pre-Annual General Meeting Information
2024-04-30_MITHRA_AGENDA_AGO-MAY-2024_FR.pdf
French 143.1 KB
2024-04-30 10:30
Proxy Solicitation & Information Statement
2024-04-30_MITHRA_PROXY-FORM_AGO-MAY-2024_EN.pdf
English 145.2 KB

Automate Your Workflow. Get a real-time feed of all Mithra Pharmaceuticals S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mithra Pharmaceuticals S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mithra Pharmaceuticals S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-01-17 NOSHAQ SA Board Other 172,574 617,814.92 EUR
2022-11-17 NOSHAQ SA Board Other 172,574 1,052,701.40 EUR
2022-07-18 NOSHAQ SA Board Other 156,250 1,006,250.00 EUR
2022-05-13 NOSHAQ SA Board Other 156,250 1,239,062.50 EUR
2022-04-13 Gordenne Valérie Other Sell 8,500 87,380.00 EUR
2022-03-29 Fornieri Francesco Board Sell 100,000 1,312,000.00 EUR
2022-03-25 Fornieri Francesco Board Sell 35,893 486,530.57 EUR
2022-03-24 Fornieri Francesco Board Sell 15,657 219,536.19 EUR
2022-03-24 Fornieri Francesco Board Sell 2,818 39,452.00 EUR
2022-03-23 Fornieri Francesco Board Sell 12,525 178,230.75 EUR

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.